PE-22-28
Spadin-derived peptide
Seven-amino-acid peptide derived from spadin that blocks the TREK-1 potassium channel, studied in cell and mouse neurobiology research.
Evidence level. Evidence comes mainly from animal or other preclinical models. About the badges
- Class
- Spadin-derived peptide
- Category
- Neuro, Cognitive & Sleep
- Type
- Single compound
- Development and regulatory status
- Not approved; preclinical research compound
What researchers study
Seven-amino-acid peptide designed from spadin (PE 12-28) blood-degradation products. Blocks the TREK-1 potassium channel, with higher reported affinity and longer in vivo action than spadin in cell and mouse studies.
Research areas
- TREK-1 potassium channel inhibition in cell assays
- Antidepressant-like behaviour in mouse tests
- Neurogenesis and synaptogenesis markers in rodent neurons
- Peptide stability compared with spadin
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- cell culture
PE 22-28 inhibited human TREK-1 in HEK cells with an IC50 of 0.12 nM versus 40-60 nM for spadin
- rodent
Spadin analogues including PE 22-28 reduced immobility time in the mouse forced swim test
- rodent
Action duration reached up to 23 h versus 7 h for spadin
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- IllumiNeuro-60Blend containing PE 22-28 with Semax and Selank derivatives
- SemaxDifferent mechanism (neurotrophin expression) studied in cognitive models
- SelankDifferent mechanism (immune and monoamine signalling) studied in anxiety-related models
